Welcome to our dedicated page for Organogenesis Holdings SEC filings (Ticker: ORGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Organogenesis Holdings Inc.'s SEC filings document a regenerative medicine issuer with Class A common stock listed on the Nasdaq Capital Market. The filings cover operating and financial results for Advanced Wound Care and Surgical & Sports Medicine products, including furnished 8-K earnings releases that separate product revenue by market category.
The company's regulatory record also includes proxy materials for annual meeting matters, director elections, advisory voting items, board governance and compensation disclosures. Other filings address Regulation FD and material-event updates for ReNu clinical and regulatory matters, capital-structure details involving Class A common stock and Series A Convertible Preferred Stock voting mechanics, and risk and governance topics tied to its product portfolio.
Organogenesis Holdings Inc. entered into an at-the-market Sales Agreement with BTIG, LLC and Citizens JMP Securities, LLC, allowing it to offer and sell shares of its Class A common stock having an aggregate offering price of up to $75,000,000 from time to time through the agents.
The shares are offered under a previously filed shelf registration statement on Form S-3 (No. 333-281392), filed with the SEC on August 8, 2024 and declared effective on August 15, 2024, pursuant to a prospectus supplement dated August 6, 2026. Sales may be made as “at the market offerings” under Rule 415(a)(4), including on the Nasdaq Capital Market. Organogenesis will pay the agents a commission of up to 3.0% of the gross sales price per share, has no obligation to sell any shares, and the offering will terminate upon termination of the Sales Agreement in accordance with its terms.
Organogenesis Holdings Inc. is establishing an at-the-market offering program to sell up to $75,000,000 of Class A common stock through BTIG and Citizens JMP as sales agents. The shares may be sold from time to time on Nasdaq or other permitted markets, with commissions of up to 3.0% of gross proceeds.
As of June 30, 2026, 128,674,548 Class A shares were outstanding and net tangible book value was $256.4 million, or $1.99 per share. If 31,645,569 shares were sold at $2.37 for $75 million in gross proceeds, as-adjusted net tangible book value would rise to $2.05 per share, implying $0.32 per-share dilution to new investors.
The company intends to use net proceeds with existing cash for working capital and general corporate purposes, including facility expansion, manufacturing enhancements, salesforce expansion, clinical studies, regulatory approvals and additional commercial insurance coverage. Organogenesis also highlights its BLA for ReNu for knee osteoarthritis pain, accepted by the FDA with a PDUFA target action date of April 24, 2027.
Organogenesis Holdings Inc. reported sharply weaker results for the quarter ended June 30, 2026. Total revenue was $ 43,755 (amounts in thousands), down from $ 101,005 a year earlier, as net product revenue fell 58% to $ 79,055 for the first six months, driven mainly by disruption from U.S. Medicare reimbursement changes and confusion following withdrawn LCDs and CMS comments on discarded product.
The company posted a quarterly net loss of $ 96,267 and year-to-date net loss of $ 149,423 (amounts in thousands), with loss per share of $ 0.77 for the quarter and $ 1.21 year-to-date. A full valuation allowance against deferred tax assets generated income tax expense of $ 30,070 (amounts in thousands) for the first half. Management undertook significant restructuring, closing a St. Petersburg facility and reducing headcount by about 226 employees, recording $ 8,781 and $ 5,099 (amounts in thousands) of restructuring charges plus $ 5,588 of R&D program termination costs. Cash and cash equivalents were $ 46,097 with working capital of $ 139.7 million; the company expects these resources and cash from sales to fund operations for at least 12 months beyond the report date. The FDA accepted the Biologics License Application for ReNu with a PDUFA target action date of April 24, 2027, while the planned Dermagraft relaunch has been delayed with no current timing projection.
Organogenesis Holdings Inc. reported substantially weaker results for the quarter and six months ended June 30, 2026. Second‑quarter net product revenue fell to $42.8 million from $100.8 million, a 58% decline, led by a 61% drop in Advanced Wound Care revenue to $36.1 million; Surgical & Sports Medicine declined 18% to $6.7 million.
Gross profit fell to $19.1 million, or 45% of net product revenue, from $73.1 million, or 73%. Operating expenses decreased 17% to $94.7 million as selling, general and administrative costs were reduced while R&D increased. Operating loss widened to $51.0 million and net loss to $96.3 million, or $(0.77) per share. Adjusted net loss was $89.0 million and Adjusted EBITDA loss $34.4 million.
For the first half of 2026, net product revenue was $79.1 million versus $187.5 million, with gross margin at 37%. The company ended June with $46.8 million in cash, cash equivalents and restricted cash and no outstanding debt obligations. Updated 2026 guidance calls for total net revenue between $179.0 million and $215.0 million, a 62%–68% decline from $564.2 million in 2025, and anticipates second‑half revenue down approximately 64%–74% year over year, compared with a prior expected decline of 45%–52%.
Organogenesis Holdings Inc. reported results from its 2026 Annual Meeting of Stockholders held on June 15, 2026. Holders of 129,564,421 shares of Class A common stock, including 38,470,359 as-converted shares from Series A Convertible Preferred Stock, were represented.
Stockholders elected nine directors, including Robert Ades and Gary S. Gillheeney, Sr., each receiving over 76 million votes for, with substantial broker non-votes reflecting street-held shares. Holders of Series A Convertible Preferred Stock also re-elected Garrett Lustig to the board by written consent.
Investors approved, on an advisory basis, the compensation of named executive officers, with 72,516,011 votes for and 12,722,258 against. They also ratified the appointment of RSM US LLP as independent registered public accounting firm for fiscal year 2026, with 128,421,160 votes for and minimal opposition.
Organogenesis Holdings Inc. reported a sharp downturn for the quarter ended March 31, 2026. Net product revenue fell to $36.3 million from $86.7 million, driven mainly by a steep decline in Advanced Wound Care sales linked to Medicare reimbursement changes and clinician confusion.
Total revenue was $37.2 million, while the company posted a net loss of $53.2 million versus $18.8 million a year earlier, with gross profit compressing significantly. Adjusted EBITDA worsened to a loss of $48.2 million, reflecting lower volume, pricing pressure, inventory write-downs and restructuring costs.
The company implemented a March 2026 restructuring, closing its St. Petersburg, Florida facility and reducing headcount by about 10%, recording $8.8 million of related charges. Despite losses, Organogenesis ended the quarter with $91.4 million in cash and access to a $75.0 million undrawn revolving credit facility, and continues investing in its Smithfield, Rhode Island biomanufacturing build-out and ReNu biologics license application.
Organogenesis Holdings Inc. reported a steep downturn for the first quarter ended March 31, 2026. Net product revenue fell to $36.3 million from $86.7 million a year earlier, a 58% decline, driven by a 63% drop in Advanced Wound Care revenue to $29.5 million. Gross profit fell to $10.5 million, or 29% of net product revenue, from $63.0 million, or 73%. Operating loss widened to $68.9 million and net loss to $53.2 million, or $(0.44) per share, compared with a $18.8 million net loss, or $(0.17) per share, in 2025. Adjusted EBITDA loss increased to $48.2 million from $12.5 million. Despite the weak quarter, the company ended March 31, 2026 with $92.1 million in cash, cash equivalents and restricted cash and no outstanding debt, and issued full-year 2026 revenue guidance of $270.0 million to $310.0 million, implying a 45% to 52% decline from 2025.
Organogenesis Holdings Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 15, 2026 at 11:00 a.m. Eastern. Investors will elect nine common directors, cast an advisory say-on-pay vote on 2025 executive compensation, and ratify RSM US LLP as independent auditor for 2026.
As of April 23, 2026, 128,674,548 shares of Common Stock and 130,000 shares of Convertible Preferred Stock, convertible into 38,470,359 Common shares, were entitled to vote together. Preferred holders can elect one board member while they hold at least 5% of the as-converted Common. Executive pay blends base salary, annual cash bonuses tied mainly to net revenue and Adjusted EBITDA, and long-term equity including stock options, RSUs and new performance share awards, which in 2025 vested at the maximum level for the first tranche based on revenue growth.
Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow exercised stock options to acquire 958 shares of Class A Common Stock on January 10, 2025 at $1.24 per share. The option was fully vested and, after the transaction, he directly holds 900,682 shares.